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Abstract 
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the 
central nervous system (CNS).  White matter lesions in MS are surrounded by areas of non-
demyelinated normal appearing white matter (NAWM) with complex pathology, including 
blood brain barrier dysfunction, axonal damage and glial activation.  Astrocytes, the most 
abundant cell type within the CNS, may respond and/or contribute to lesion pathogenesis.  
We aimed to characterise the transcriptomic profile of astrocytes in NAWM to determine 
whether specific glial changes exist in the NAWM which contribute to lesion development or 
prevent disease progression.  
 Astrocytes were isolated from control and NAWM by laser capture microdissection 
(LCM), using glial fibrillary acidic protein (GFAP) as a marker, and the astrocyte 
transcriptome determined using microarray analysis.  452 genes were significantly 
differentially expressed (208 up-regulated and 244 down-regulated)&DQG p-
YDOXH).  Within the NAWM, astrocytes were associated with significant upregulation of 
genes involved in the control of iron homeostasis (including metallothionein-1 and -2, ferritin 
light chain and transferrin), oxidative stress responses, the immune response and 
neurotrophic support.  These findings suggest a neuroprotective role of astrocytes in the 
NAWM in MS. 
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Highlights: 
x GFAP is the optimal marker to label astrocytes for laser capture microdissection 
x Astrocytes in the NAWM express transcripts associated with iron homeostasis 
x Astrocytes increase expression of oxidative stress & immune response-related genes 
 
  
3 
 
1. Introduction 
Multiple sclerosis (MS) is a complex disease neuropathologically characterised by 
demyelinated lesions distributed throughout the brain and spinal cord, inflammation, 
axonal/neuronal damage, gliosis, oxidative stress, excitotoxicity and blood brain barrier 
(BBB) dysfunction (Stables et al., 2010). Subtle pathological changes exist in the normal 
appearing white matter (NAWM) that are not detected by standard magnetic resonance 
imaging (MRI) and are only identifiable upon immunohistochemical evaluation, including mild 
inflammation, microglial activation, astrogliosis, axonal swelling, cellular infiltration and 
reduced myelin density (Moll et al., 2011, Allen et al., 2001, Allen and McKeown, 1979, 
Kutzelnigg et al., 2005, Lund et al., 2013). The cause of these changes in the white matter in 
MS are unknown but may be a result of underlying molecular pathology, or they may 
represent lesions that are beyond the sensitivity of current imaging techniques (Mistry et al., 
2011). In order to better understand the pathogenesis of the disease and the mechanisms 
underlying lesion development, the processes that occur within the surrounding NAWM need 
to be identified.  
Astrocytes play a key role in maintaining the extracellular environment and 
supporting neurons (Sobel & Moore 2008). While it has been suggested that astrocytes play 
a neuroprotective role in MS by inhibiting demyelination (Miljkovic et al., 2011), releasing 
anti-inflammatory cytokines (Bsibsi et al., 2006) and secreting proteins involved in myelin 
repair and neurotrophins to support regeneration of neurons (Marz et al., 1999, Moore et al., 
2011a, Moore et al., 2011b, Mason et al., 2001, Miljkovic et al., 2011), it has also been 
proposed that astrocytes are detrimental in disease pathogenesis by releasing pro-
inflammatory cytokines, contributing to BBB dysfunction (Argaw et al., 2006, Argaw et al., 
2012) and preventing oligodendrocyte precursor cell (OPC) maturation into remyelinating 
oligodendrocytes (Messersmith et al., 2000, Sarchielli et al., 2008). 
The advancement of transcriptomic technology enables studies to be carried out to 
identify the genetic profile associated with the pathogenesis of disease. To date, gene 
expression profiling in MS has focussed on the differences between demyelinated lesions 
and neurological control WM, as reviewed (Dutta and Trapp, 2012, Dutta, 2013). MS is a 
heterogeneous and progressive disease where the architecture of the brain tissue is 
constantly changing depending on the stage of the disease (Bradl and Lassmann, 2012). 
Consequently, investigating NAWM as opposed to established lesions may identify factors 
that initiate or prevent disease progression compared to the genetic profile of an already 
established demyelinated lesion. Yet despite this, to date only four microarray studies have 
investigated the gene expression profile of NAWM in MS (Graumann et al., 2003, Lindberg 
et al., 2004, Zeis et al., 2008, Mycko et al., 2012) with transcriptomic changes identified in 
whole tissue, constituting a heterogeneous cell population. 
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Laser capture microdissection (LCM) allows the isolation of particular regions or cells 
of interest from post-mortem material and can be used in conjunction with microarray 
analysis to identify differentially expressed genes in an enriched cell population. To date, 
only two studies have combined LCM with microarray analysis in MS research, including 
analysis of the gene expression profile of blood vessels (Cunnea et al., 2010) and LCM-ed 
areas of MS lesions and NAWM (Mycko et al., 2012).  
Transcriptomic profiling of astrocytes in the NAWM in MS may identify disease 
relevant gene expression changes and elucidate pathological processes that can be 
manipulated through therapeutic intervention at an earlier stage in the disease, preventing 
lesion development and ultimately disease progression. Therefore, the current study used 
immuno-guided LCM to isolate astrocytes from NAWM and control WM, followed by gene 
expression profiling. Our findings identify the major astrocyte-associated gene differences 
between NAWM and control WM and highlights novel candidate genes. This contributes to 
our understanding of the potential role of astrocytes in restricting MS lesion development. 
 
2. Materials and Methods 
2.1 Human central nervous system (CNS) tissue 
CNS tissue was obtained from the UK Multiple Sclerosis Tissue Bank Wales 
Research Ethics Committee (Ref. No. 08/MRE09/31).  Snap frozen NAWM and control WM 
samples used in the microarray study were selected based on their neuropathological 
assessment and, where possible, the cases were matched for age and gender (Table 1). 
The ribosomal integrity number (RIN) of each frozen tissue block was assessed prior to LCM 
using a previously reported method (Bahn et al., 2001, Waller et al., 2012). Only samples 
with a pre-LCM RIN >3.0 and brain pH >6.5 were taken forward for immuno-LCM. The 
quantity of RNA from each sample was analysed using a NanoDrop 1000 spectrophotometer 
(Thermoscientific, UK) and the quality of RNA assessed on a 2100 bioanalyzer (Agilent, Palo 
Alto, CA, USA).  
 
2.2 Immunohistochemistry  
To determine the most suitable astrocyte marker that clearly labelled individual 
astrocytes for use in immuno-guided LCM and to visualise the proteins encoded by key 
candidate genes, immunohistochemistry (IHC) was performed using a standard avidin-biotin 
complex (ABC) method with diaminobenzidine (DAB) as substrate (Vector Laboratories, UK) 
(Table 2 lists the antibodies used). Negative controls including isotype-specific antibody 
controls and the omission of the primary antibody confirmed the specificity of staining. Dual 
labelling with the astrocyte marker GFAP was performed as previously described (Fluteau et 
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al., 2015) to investigate astrocyte association with FTL. Images were acquired using a BX61 
Olympus microscope and CellR image software. 
 
2.3 Immuno-laser capture microdissection (LCM) of astrocytes and RNA extraction 
Astrocytes were isolated using a rapid immuno-LCM method, as previously described 
in detail (Waller et al., 2012). Approximately 1,000 glial fibrillary acidic protein (GFAP+) 
astrocytes were isolated from each case using the PixCell II laser capture microdissection 
system (Arcturus Engineering, Mountain View, CA, USA). Total RNA was extracted using 
WKH3LFR3XUH51$LVRODWLRQNLWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV$UFWXUXV
BioScience, UK). The quantity and quality of the extracted RNA was determined using a 
Nanodrop 1000 spectrophotometer (Thermoscientific, UK) and a 2100 Bioanalyzer, 
respectively (Agilent, USA). Only those samples identified as having a RIN >2.0 post-LCM 
were taken forward for microarray analysis. 
 
2.4 RNA amplification and microarray hybridization 
7KHWDUJHWODEHOOHGP51$ZDVSUHSDUHGIROORZLQJWKH*HQH&KLS¶,97([SUHVV
amplification protocol (Affymetrix, UK). In brief, total RNA was reverse transcribed to 
synthesise the first-strand cDNA by annealing RNA with a T7 oligo(dT) primer. The single 
stranded cDNA was converted into double-stranded cDNA by a reaction with a DNA 
polymerase and RNase H. An overnight in vitro transcription (IVT), incorporating an IVT 
labelling master mix, allowed the synthesis of multiple copies of biotin-labelled antisense 
RNA from the double stranded cDNA template. Following clean-up and purification the 
quality of the labelled RNA was checked on the Agilent 2100 Bioanalyzer.  
Approximately 6.5µg amplified labelled RNA was fragmented and hybridised to 
Affymetrix Human Genome U133 Plus 2.0 Array chips for 16 hours at 45°C in a rotating 
oven at 60rpm. Using the Fluidics Station 400, and Gene Chip Operating System, the 
hybridisation cocktail was removed and a series of washing steps followed to remove any 
unbound RNA, before each microarray was stained. Each microarray chip was scanned 
using the GeneChip 3000 scanner to determine the fluorescence intensity of hybridised 
transcripts.  
 
2.5 Microarray analysis 
The Affymetrix Gene Expression Console was used for quality and control analysis of 
the data, the image or .CEL files were imported to GeneSpring version 7.0 (Agilent, USA) 
and normalised to the median of all genes, prior to statistical analysis, to identify differentially 
expressed genes. Transcripts were defined as being significantly, differentially expressed if 
they showed a minimum fold change (FC) of >1.5 and a p-value of <0.05 (unpaired t-test). 
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Significantly, differentially expressed genes were classified according to their biological 
function using the Database for Annotation Visualisation and Integrated Discovery (DAVID) 
(Huang da et al., 2009a, Huang da et al., 2009b) and Kyto Encyclopedia of Genes and 
Genomes (KEGG) pathway analysis was carried out to identify specific pathways.  
 
2.6 Validation of microarray data: quantitative real-time polymerase chain reaction (qPCR) 
RNA was extracted from LCM-ed astrocytes from 9 additional frozen cases (4 control 
WM and 5 NAWM), which had not been used for the microarray studies.  qPCR was 
performed using IDT PrimeTime qPCR assays (Integrated DNA Technologies, UK) 
containing 50 ng cDNA, 500nM primers, 250nM probe, and Brilliant qPCR mix (Agilent, UK)  
in a total volume of 10Pl, for details of primer sequences see Table 3.  Following 
denaturation at 95oC for 3 min the products were amplified (40 cycles at 95oC for 10s and 
60oC for 30s) using a CFX384 TouchTM RT PCR detection system (Bio-Rad, UK).  E-actin 
was amplified on each plate to normalise expression levels of target genes between different 
samples using the ''Ct calculation (ABI) and to assess assay reproducibility (Livak and 
Schmittgen, 2001). 
 
3. Results 
3.1 GFAP is currently the best marker of astrocytes for immuno-LCM 
To determine the optimal marker of astrocytes to use for isolation using immuno-
LCM, a panel of currently described astrocyte markers was employed.  GFAP 
immunoreactivity was associated with the cell body and extending processes, and labelled 
astrocytes with a distinct stellate morphology (Figure 1a).  S100B immunoreactivity was 
predominantly associated with astrocyte cell bodies, and was also associated with small, 
spherical cells morphologically resembling oligodendrocytes (Figure 1b).  In comparison to 
antibodies against GFAP and S100B, which predominantly stained astrocyte cell bodies and 
immediate cell processes, both excitatory amino acid transporter-1 (EAAT1) (Figure 1c) and 
EAAT2 (Figure 1d) antibodies labelled the extending delicate processes of astrocytes, the 
pattern of which varied greatly across the sample cohort.  In contrast, glutamine synthetase 
(GS) immunoreactivity was not as extensive as GFAP and was associated with the astrocyte 
cell body and immediate stumpy processes (Figure 1e). GS staining was not restricted to 
stellate astrocytes but also labelled the cytoplasm of small, spherical cells morphologically 
resembling oligodendrocytes.  Aldehyde dehydrogenase 1 family member L1 (ALDH1L1) 
preferentially labelled cortical astrocytes, with little staining of WM. Within the cortex, 
ALDH1L1 immunoreactivity was restricted to the cell body and did not extend to the 
astrocyte processes, and was also associated with small spherical cells morphologically 
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resembling oligodendrocytes (Figure 1f). Based on astrocyte specificity, clear labelling of 
individual cells and ability to identify the maximum number of astrocytes, GFAP was selected 
as the best astrocyte marker for the further studies.  
 
3.2 Confirmation of astrocyte enrichment  
In order to confirm that the extracted RNA from each sample represented an 
enriched astrocyte population, specific transcript expressions were investigated. High levels 
of GFAP transcripts were found (astrocyte: probe set id 203540_at, mean signal intensity 
5995.0; range, 1263.7-20549.3), but low levels of CD34 (endothelial cell: probe set id 
209543_s_at, mean signal intensity 50.6; range, 14.7-98.4), CD68 (microglia: probe set id 
203507_at, mean signal intensity 23.7; range, 4.1-64.1), and OLIG-2 oligodendrocyte: probe 
set id 213825_at, mean signal intensity 290.3; range, 133.5-520.7) confirming the extracted 
RNA from GFAP+ LCM-ed cells represented an enriched astrocyte population. Moderately 
high levels of a neuronal transcripts were detected (NFL: probe set id 221805_at, mean 
signal intensity 3328.6; range, 368.9-5264.2), which may reflect the close proximity of 
astrocytes to axons.  
 
3.3 NAWM associated changes in the astrocyte transcriptome 
The transcription profiles of laser-captured astrocytes from NAWM and control WM 
were generated using Human Genome U133 Plus 2.0 Arrays, which comprise 1.3x106 
unique oligonucleotide sequences, including >47,000 transcripts and variants of 33,000 
genes.  Between 7.5% and 38.2% of the probe set sequences were present across all 
samples (mean [range]): NAWM (32.1% [22.5-36.4%]); control WM (26.6% [7.5-38.2%]).   
Gene expression analyses are sensitive to the presence of sample outliers, therefore 
rigorous quality control procedures were used to ensure the highest possible level of quality 
for both datasets.  Sample outliers were identified by visual inspection after clustering the 
samples using hierarchical clustering and 3 cases (MS5, C3 and C5) were removed from 
subsequent analysis (Figure 2).  The robust multi-array average (RMA) was re-analysed 
after these cases were removed and principle component analysis was performed on the 
significant, differentially expressed genes of 4 NAWM and 3 control WM cases (the 
expression dataset is freely available at Gene Expression Omnibus, accession number 
GSE83670).  Transcript clusters showed no association with age, gender, post-mortem 
delay or pH. 
3,375 genes (1,778 up-regulated, 1,596 down-regulated) had altered expression in 
NAWM astrocytes compared to control astrocytes. Transcripts were deemed significantly, 
GLIIHUHQWLDOO\H[SUHVVHGLIWKH\KDGD)&DQGDS-YDOXHXS-regulated and 244 
down-regulated, (Supplementary Table 1).  Functional grouping analysis identified that the 
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dysregulated genes were associated with the immune response, homeostasis, response to 
metal ion binding, response to hypoxia, cell signalling, cytoskeleton, RNA processing/protein 
metabolism, the cellular response to stress, the synapse, ubiquitin-mediated proteolysis, 
transport and transcription (Table 4).  
 
3.3.1 Increased expression of transcripts associated with the regulation of iron homeostasis 
and the response to oxidative stress 
Assessing the top 20 differentially upregulated genes (Table 5), identified 6 genes 
related to the regulation of iron homeostasis and the response to oxidative stress: 
metallothionein 1X [MT1X] probe set 208581_x_at, FC=2.23, p=0.042, metallothionein 1G 
[MT1G] probe set 204745_x_at, FC=2.26, p=0.031, metallothionein 2A [MT2A] probe set 
212185_x_at, FC=2.52, p=0.032, metallothionein 1 pseudogene 2 [MT1p2] probe set 
211456_x_at, FC=2.22, p=0.044, ferritin light chain [FTL] probe set 212788_x_at, FC=2.24, 
p=0.030, and transferrin [TF] probe set 214064_at, FC=2.21, p=0.048. 
 
3.3.2 NAWM-associated increase in immune response-related transcripts 
 Functional grouping identified enrichment of genes associated with the immune 
response, with the majority of genes (15/19, Supplementary Table 1) upregulated in NAWM 
compared to control WM. These included CD74 (CD74 probe set 209619_at, FC=2.73, 
p=0.008), complement component 1 (C1QC probe set 225353_s_at, FC=1.77, p=0.016), 
complement component 3 (C3 probe set 217767_at, FC=1.94, p=0.035), interleukin-17C 
(IL17C probe set 224079_at, FC=1.54, p=0.039), interleukin-4 receptor (IL4R probe set 
203233_at, FC=1.54, p=0.013), major histocompatibility complex class II (HLA-DPA1 probe 
set 211990_at, FC=2.01, p=0.003) (HLA-DPB1 probe set 201137_s_at, FC=1.85, p=0.006), 
prostaglandin-endoperoxide synthase 2 (PTGS2 probe set 204748_at FC=-1.56, p=0.021 
and transforming growth factor beta 3 (TGF-B3 probe set209747_at, FC=1.55, p=0.024 ). 
 
3.3.3 NAWM-associated dysregulation of signalling transcripts 
 Analysis of the astrocyte transcriptome in NAWM in MS also identified dysregulation 
of genes associated with multiple signalling pathways, including mitogen-activated protein 
kinase (MAPK) signalling [mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4 
probe set 218181_s_at, FC=1.54, p=0.016); mitogen-activated protein kinase-activated 
protein kinase 2 (MAPKAPK2 probe set 201460_at, FC=1.70, p=0.039)], insulin signalling 
[insulin-like growth factor binding protein-5 (IGFBP5 probe set 211959_at, FC=2.24, 
p=0.024; probe set 203424_s_at, FC=1.71, p=0.01)], calcium signalling [calcium channel, 
voltage dependent N-type, alpha 1B subunit (CACNA1B probe set 235781_at, FC=-1.68, 
p=0.039); calmodulin (CALM1 probe set 211985_s_at, FC=-1.91, p=0.04)] and ubiquitin 
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signalling pathways [small ubiquitin-related modifier 1 (SUMO1 probe set 203871_at, FC=-
1.63, p=0.001); ubiquitin specific peptidase 43 (USP43 probe set 237439_at, FC=-1.71, 
p=0.012)]. 
 
3.4 Validation of key gene expression changes 
Astrocyte expression of the protein encoded by the candidate genes identified in the 
microarray study was confirmed by IHC. A regular pattern of ferritin light chain 
immunoreactivity was detected in all NAWM and control WM cases with staining associated 
with cells morphologically resembling microglia and astrocytes. Dual labelling confirmed a 
proportion of these ferritin light chain immunopositive cells were GFAP+ astrocytes (Figure 
3a). Calmodulin immunoreactivity was associated with the astrocyte cell bodies and 
immediate processes (Figure 3b).  Dense metallothionein immunoreactivity was a common 
feature across all MS NAWM and control cases investigated, and was associated with the 
cell body and extending processes of cells with a typical astrocyte stellate morphology 
(Figure 3c).  The altered expression of candidate genes was validated by qPCR on LCM-
isolated astrocytes from additional cases.  The NAWM was associated with significantly 
higher expression of FTL (p=0.008), and non-significant decreased expression of CALM1. 
(Figure 3d).   
 
4. Discussion 
Astrocytes play a key role in regulating homeostasis within the CNS, providing 
neurotrophic support, contributing to immune surveillance and maintaining BBB integrity 
(Pekny et al., 2015), with increasing evidence indicating a potential role of these glial cells in 
the pathogenesis of MS lesions (Brosnan and Raine, 2013).  The radiologically normal WM 
surrounding these lesions is pathologically abnormal (Allen et al., 2001), and it is likely that 
identifying gene expression changes in astrocytes in the NAWM in MS may identify whether 
astrocytes contribute to, or prevent lesion initiation and progression.  Several papers have 
discussed the complexity of astrocytes in MS, with emphasis on their dual function: on the 
one hand astrocytes are neurotoxic, through a deleterious immune response, increasing 
BBB permeability and inhibiting remyelination; whilst on the other these glial cells are 
neuroprotective, supporting oligodendrocyte remyelination and axonal regeneration 
(Williams et al., 2007, Nair et al., 2008, Brosnan and Raine, 2013).  To date five studies 
have performed RNA profiling of the NAWM in MS compared to control WM, one recent 
study characterising the microRNA profile (Guerau-de-Arellano et al., 2015) and four studies 
have reported mRNA expression changes (Graumann et al., 2003, Lindberg et al., 2004, 
Zeis et al., 2008, Mycko et al., 2012). All of these studies were carried out using RNA from 
whole tissue extracts, which thus comprised a heterogeneous cell population within the 
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NAWM.  To our knowledge, the current study is the first to perform microarray analysis on 
laser captured astrocytes from the NAWM, identifying increased expression of genes 
associated with the regulation of iron homeostasis, the response to oxidative stress, the 
immune response and neurotrophic support, suggesting a neuroprotective role of these cells 
in the NAWM in MS. 
We have previously demonstrated that immuno-LCM of autopsy tissue enables the 
isolation and enrichment of specific cell populations for further downstream analysis (Waller 
et al., 2012).  An increasing number of studies in a range of neurological diseases have used 
this approach to identify disease-relevant, cell-specific gene expression changes (Boone et 
al., 2013, Chu et al., 2009, Kumar et al., 2013, Pietersen et al., 2009, Simpson et al., 2011, 
Baker et al., 2015, Simpson et al., 2015).  To date, only two studies have employed LCM in 
the investigation of human MS cases: one identifying gene expression changes in total 
extracts from NAWM, peri-lesional and lesional regions compared to control WM (Mycko et 
al., 2012) and the other identifying transcriptomic changes in the vascular compartment in 
MS (Cunnea et al., 2010); with neither study specifically assessing changes in the astrocyte 
transcriptome.   
Iron is vital in the synthesis of myelin and neurotransmitters, and plays an important 
role in oxygen transport, DNA synthesis and repair, and mitochondrial energy production 
(Crichton et al., 2011, Todorich et al., 2009, Levenson and Tassabehji, 2004).  Within the 
brain the majority of iron is present in the inactive ferric form (Fe3+), with the remainder 
present in the active ferrous form (Fe2+).  Levels of iron within the CNS are strictly regulated 
as both deficient and excess concentrations impact cell viability (Li and Reichmann, 2016).  
Dysregulation of genes involved in the transport and storage of iron, including transferrin 
(TF) and ferritin (FT) respectively, leads to an increase in Fe3+ resulting in oxidative damage 
(Connor and Menzies, 1995).  Increased iron deposition is associated with oligodendrocyte 
cytotoxicity and myelin loss in MS, with elevated levels detected at the peri-lesional margin 
(Bagnato et al., 2011, Hametner et al., 2013).  Furthermore, excess iron can amplify 
microglial activation stimulating an increase in the secretion of pro-inflammatory cytokines, 
and can directly damage mitochondria resulting in increased oxidative stress (Williams et al., 
2012, Haider et al., 2011).   
Unlike oligodendrocytes and microglia, astrocytes are resilient to the cytotoxic effects 
of excess iron (Gaasch et al., 2007) which may, in part, be attributable to their increased 
expression of MT that scavenge transition metal ions and free radicals.  Increased 
expression of MT by astrocytes forms part of the inflammatory and defence response, and 
has been reported in MS (Penkowa et al., 2003) and its animal model, experimental 
autoimmune encephalomyelitis (EAE) (Penkowa and Hidalgo, 2000, Espejo et al., 2005).  
MT treatment has also been shown to prevent demyelination and axonal damage, and 
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decrease expression of pro-inflammatory cytokines in EAE (Penkowa and Hidalgo, 2001, 
Penkowa and Hidalgo, 2003), providing direct evidence that increasing astrocytic expression 
of MT is a valid potential therapeutic target.  The significant increased expression of iron 
regulatory genes identified in the current study, including MT1, MT2, FTL and TF, suggest a 
neuroprotective response whereby astrocytes adapt to protect the NAWM from widespread 
iron-induced oxidative damage. 
 The present study also revealed the significant upregulation of genes associated with 
the immune response, supporting previous gene expression studies performed on NAWM in 
MS (Lindberg et al., 2004).  Interestingly there was no significant upregulation in expression 
of the pro-inflammatory cytokines interferon-Ȗ or tumour necrosis factor-Į, which are 
classically associated with the pathogenesis of MS (Kierdorf et al., 2010), but levels of TGF-
ǀ3, an astrocyte derived regulator of neuronal survival (Krieglstein et al., 2002), were 
significantly increased in the NAWM, suggesting a neuroprotective role for astrocytes in the 
NAWM.  Furthermore, the current study identified significant downregulation of PTGS2, 
which encodes cyclooxygenase-2 (COX2), an enzyme which has been shown to stimulate 
the production of prostanoids that contribute to chronic inflammation (Minghetti, 2004), 
providing further support that astrocytes in the NAWM are neuroprotective. 
 Our analysis also revealed differential expression of genes associated with receptor 
mediated signalling pathways in NAWM, including MAPK and calcium signalling, confirming 
previous reports (Graumann et al., 2003, Zeis et al., 2008).  The current study identified 
significant upregulation of MAPKAPK2 and MAPK4, both of which are linked to ischaemic 
preconditioning and oxidative stress in MS (Graumann et al., 2003).  Dysfunction of calcium 
signalling, calcium pumps and exchangers are linked to axonal injury and neuronal 
dysfunction in MS, where the abnormal influx, extrusion, buffering and sequestration results 
in a calcium imbalance which may initiate detrimental mechanisms (Kurnellas et al., 2007).  
Dysregulation of intracellular signalling pathways is also a feature of acute lesions (Whitney 
et al., 1999), active lesion margins (Mycko et al., 2012) and cortical pathology in MS (Dutta 
et al., 2007).    
In this study we trialled a comprehensive panel of astrocyte markers and determined 
that immunolabelling for GFAP is currently the best approach to confidently visualise 
astrocytes for LCM isolation from post-mortem tissue.  However, while GFAP is widely used 
as a reliable marker of astrocytes, it should be acknowledged that not all astrocytes are 
GFAP+ (Sofroniew and Vinters, 2010), therefore our findings are biased towards the gene 
expression profile of the reactive astrocyte population.  Furthermore, the technical limitations 
of LCM resulted in the isolation of an enriched, but not pure, population of GFAP+ astrocytes.  
Transcriptomic analysis generates large datasets, therefore to limit the number of genes 
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submitted for analysis we examined genes that differed by a minimum of 1.5-fold, which may 
have led to the loss of valuable information and excluded genes whose more moderate 
changes in expression have a significant impact on translation.   
 
5. Conclusions 
In summary, the current study defines the complex gene expression profile of 
astrocytes in the NAWM in MS and suggests a neuroprotective role against iron-induced 
oxidative damage, additional functional studies would be required to fully validate this 
finding.  Dysregulation of CNS iron levels has been linked to several neurodegenerative 
GLVHDVHVLQFOXGLQJ$O]KHLPHU¶VGLVHDVHDQG3DUNLQVRQ¶VGLVHDVHZKHUHFXUUHQWLURQ
chelating therapeutics have been designed to block the redox-activity of iron and prevent its 
contribution to disease progression (Farina et al., 2013). Treatments to counteract the 
neurotoxic effects of iron and oxidative stress, and/or to promote astrocytic expression of MT 
may also potentially benefit MS patients. 
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Table 1.  Age, gender, PMI, and cause of death of cases. 
 
Case Age (y) Gender PMI (h) Cause of death 
MS1* 72 F 8 Bronchopneumonia 
MS2* 77 F 9 Bronchopneumonia 
MS3* 86 F 11 Bronchopneumonia 
MS4* 78 F 5 Metastatic carcinoma of bronchus 
MS5* 46 M 7 Pneumonia  
MS6 75 M 8 Cerebrovascular accident 
MS7 42 F 11 Bronchopneumonia 
MS8 46 M 7 Pneumonia 
MS9 77 F 7 Pneumonia 
MS10 73 M 8 Pneumonia 
C1* 59 F 5 Bronchopneumonia 
C2* 64 M 18 Cardiac failure 
C3* 35 M 22 Carcinoma of the tongue 
C4* 60 M 13 Ovarian cancer 
C5* 69 F 33 Lung cancer  
C6 35 M 22 Carcinoma of the tongue 
C7 75 M 17 CVA 
C8 91 F 22 Bronchial pneumonia 
C9 78 F 23 Unknown 
All MS cases were classified as SPMS 
M, male; F, female; PMI, post mortem interval; *cases used in microarray study 
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Table 2.  Antibody source and specificity.  
 
Primary antibody Isotype Dilution  Supplier  
GFAP Rabbit IgG 1:1000 Dako, UK 
S100B Rabbit IgG 1:4000 Dako, UK 
EAAT1 Mouse IgG2A 1:20 Leica Microsystems, UK 
EAAT2 Mouse IgG2A 1:20 Leica Microsystems, UK 
GS Mouse IgG2A 1:1000 Dako, UK 
ALDHL1 Rabbit IgG 1:50 Abcam, UK 
FTL Rabbit IgG 1:400 Abcam, UK 
CALM1 Rabbit IgG 1:100 Sigma, UK 
MT Mouse IgG 1:200 Dako, UK 
IgG: immunoglobulin; GFAP: glial fibrillary acidic protein; EAAT: excitatory amino acid 
transporter; GS: glutamate synthetase; ALDHL1: aldehyde dehydrogenase L1; FTL: ferritin 
light chain; CALM1: Calmodulin; MT: metallothionein clone E9 
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Table 3.  Genes selected to validate microarray data. 
Gene  Sequence 
ACTB Probe 56-FAM/CTGCCTCCA/ZEN/CCCACTCCCA/3IABkFQ 
 Primer 1 GTCCCCCAACTTGAGATGTATG 
 Primer 2 AAGTCAGTGTACAGGTAAGCC 
CALM1 Probe 56-
FAM/CTGCTTCTC/ZEN/TGATCATTTCATTTCATCTACTTCTTCATCT
G/3IABkFQ 
 
 Primer 1 GTGCAGCAGAACTACGTCA 
 Primer 2 TCTTCATTTTGCAGTCATCATCTG 
FTL Probe 56-FAM/CCTCCAGCC/ZEN/AATAGGCAGCTTTCT/3IABkFQ 
 Primer 1 CTCACTCTCAAGCACGACTAAG 
 Primer 2 GGTCCAAGGCTTGTTAGGATAG 
MT2A Probe 56-FAM/AGCTCGCCA/ZEN/TGGATCCCAACT/3IABkFQ 
 Primer 1 AGCTTTTCTTGCAGGAGGTG 
 Primer 2 GCAACCTGTCCCGACTCTA 
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Table 4. DAVID analysis of microarray data.  Functional grouping of significant, 
differentially expressed genes in MS NAWM astrocytes versus control WM astrocytes. 
 
Functional Group Number of genes p-value 
RNA processing 19 0.013 
Immunity and defence 34 0.021 
Intracellular signalling cascade 28 0.0035 
Protein metabolism and modification 70 0.0015 
Cytoskeleton  35 0.026 
Homeostasis   
Neuronal development 12 0.046 
Response to metal ions 7 0.031 
Cellular cation homeostasis 10 0.046 
Response to hypoxia 8 0.012 
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Table 5. Top 20 differentially up-regulated genes.  Six genes from the top 20 up-
regulated genes were related to the homeostasis of iron and oxidative stress (highlighted in 
bold). 
 
Probe set id p-value Fold change Gene symbol Gene Title 
209619_at 0.008 2.73 CD74 CD74 molecule, major histocompatibility 
complex, class II invariant chain 
225368_at 0.034 2.63 HIPK2 Homeodomain interacting protein kinase 2 
209343_at 0.029 2.57 EFHD1 EF-hand domain family, member D1 
212185_x_at 0.032 2.52 MT2A Metallothionein 2A 
225097_at 0.028 2.43 HIPK2 Homeodomain interacting protein kinase 2 
204037_at 0.018 2.39 LPAR1 Lysophosphatidic acid receptor 1 
225207_at 0.039 2.35 PDK4 Pyruvate dehydrogenase kinase, isozyme 4 
235617_x_at 0.044 2.29 - - 
219236_at 0.027 2.28 PAQR6 Progestin and adipoQ receptor family member VI 
204745_x_at 0.031 2.26 MT1G Metallothionein 1G 
205117_at 0.010 2.25 FGF1 Fibroblast growth factor 1 (acidic) 
211959_at 0.024 2.24 IGFBP5 Insulin-like growth factor binding protein 5 
212788_x_at 0.030 2.24 FTL Ferritin, light polypeptide 
208581_x_at 0.042 2.23 MT1X Metallothionein 1X 
229048_at 0.028 2.22 - - 
211456_x_at 0.044 2.22 MT1P2 Metallothionein 1 pseudogene 2 
214064_at 0.048 2.21 TF Transferrin 
201721_s_at 0.017 2.18 LAPTM5 Lysosomal multispanning membrane protein 5 
209000_s_at 0.037 2.18 SEPT8 Septin 8 
218251_at 0.011 2.16 MID1IP1 MID1 interacting protein-1 
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